SCHEMBL5217610

SCHEMBL5217610

c1cc(-c2cnn(-c3ccc(C4CCCCC4)cc3)c2)ncn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MELK Q14680 9/20 0.41
CAMKK2 Q96RR4 1/20 0.40
PDE10A Q9Y233 1/20 0.39
CYP11B2 P19099 1/20 0.38
DGAT1 O75907 1/20 0.38
GSK3B P49841 1/20 0.37
S1PR1 P21453 1/20 0.36
MIF P14174 1/20 0.35
KDM4E B2RXH2 1/20 0.35
GLA P06280 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HIF1A Q16665 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
GRM4 Q14833 2/20 0.34
DRD2 P14416 1/20 0.34
DRD4 P21917 1/20 0.34
DRD3 P35462 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30795251 0.84 GRM5 (0.49) MELKPDE10ACYP11B2DGAT1KDM4E
SCHEMBL3919757 0.84 GRM5 (0.49) MELKPDE10ACYP11B2DGAT1KDM4E
SCHEMBL12203764 0.78 PDE10A (0.46) MELKPDE10AKDM4ESMN1; SMN2GRM4
SCHEMBL5668065 0.77 GRM4 (0.48) MELKPDE10AGRM4
SCHEMBL5215451 0.76 DHODH (0.41) SMN1; SMN2GRM4DRD2DRD4DRD3
SCHEMBL28245414 0.76 PDE10A (0.46) MELKPDE10AGRM4
SCHEMBL5216629 0.74 PDE10A (0.44) MELKPDE10AGRM4
SCHEMBL5220848 0.74 PDE10A (0.44) PDE10AMIFKDM4EKMT2ASMN1; SMN2
SCHEMBL182016 0.73 ALKBH2 (0.46) MELKPDE10AKMT2AGRM4
SCHEMBL5217035 0.72 GRM4 (0.44) MELKPDE10ACYP11B2GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100387594-C Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO INC (US) 2008-05-14 CN claimed
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 EP claimed
US-20060194807-A1 Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. 2006-08-31 US claimed
CN-1795184-A Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO INC (US) 2006-06-28 CN claimed
EP-1613614-A2 DI-ARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2006-01-11 EP claimed
EP-1458383-A4 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-05-25 EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 US claimed
WO-2004089303-A2 DI-ARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2004-10-21 WO claimed
EP-1458383-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C MELK 366/4885CAMKK2 862/4885PDE10A 964/4885
US-20060194807-A1 Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRM1, GRIK5 MELK 1415/4885CAMKK2 1399/4885PDE10A 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.